RANTUM’S SURGICAL INSTRUMENTS PLATFORM SECURES NEW GROWTH FINANCING AND CONTINUES ITS STRATEGIC BUY-AND-BUILD

• Further add-on acquisitions strengthen the group and expand its product portfolio into high-growth premium segments
• Eurazeo provides financing to support the continued execution of the acquisition strategy
• Strategic integration of the add-ons to unlock further operational synergies

Rantum Capital’s MedTech group in the field of surgical instruments (the “Group”) invests in leading manufacturers of premium surgical instruments. Its companies cover the entire value chain, from development and in-house manufacturing through to regulatory approval, and primarily serve leading international MedTech OEMs in open and minimally invasive surgery.

Rantum Capital laid the foundation for the Group in April 2026 with the acquisition of Tontarra Medizintechnik GmbH. The subsequent acquisitions of S. u. A. Martin GmbH & Co. and Getsch+Hiller Medizintechnik GmbH have strengthened the Group’s market position, rounded out its product portfolio with strategically important growth segments, and further broadened its customer base.

The newly raised growth financing will fund the acquisitions mentioned above. In addition, the financing package provided by Eurazeo creates the headroom for further targeted acquisitions as the Group continues its strategic build-out.

Christoph Gerber, CEO of the Group, commented: “We are delighted to have gained Eurazeo as a strong and highly regarded partner that will support our growth trajectory over the long term. Through further targeted acquisitions of medical technology companies, we can expand our product and technology portfolio, win new customers, enter new markets, and thereby sustainably strengthen our Group’s competitive position.”

Gilles Djordjevic of Rantum Capital added: “The partnership with Eurazeo is an important milestone for the Group. The financing lays the groundwork for us to continue executing our growth strategy, complete further acquisitions, and expand our market position in the attractive and growing surgical instruments market.”

The Group and Rantum Private Equity Fund II were advised on the various transactions by CMS Hasche Sigle Partnerschaft (Dr. Hendrik Hirsch, Dr. Maximilian Stark, Pia Konle), Grant Thornton (Klaus-Martin Hausmann, Dr. Achim Kestler) and Codex Partners (Dr. Rüdiger Maaß, Leonie Bobenstetter). Network Corporate Finance (Nicholas Rusch, Charlie Böhm) acted as exclusive debt advisor to the Group and Rantum Private Equity Fund II. The debt financing was provided by Eurazeo (Natalie Venc, Jan Christopher Müller, Nicolas Kinderstuth). Hogan Lovells Cadwalader (Thomas Freund, Tiziana Daxenberger) provided legal counsel to the Group and Rantum Private Equity Fund II on the negotiation of the debt financing.

About the Group
The Group is a leading manufacturer of precision surgical instruments with four sites and nearly 300 employees. Its broad, complementary product portfolio spans open and minimally invasive surgery, endoscopy and spinal surgery, arthroscopy and laparoscopy, as well as micro- and neurosurgery. As a fully integrated OEM and contract manufacturer, the Group covers the entire value chain, from development and contract manufacturing to private-label products and acting as a certified legal manufacturer. The Group is further distinguished by its certified quality management systems and long-standing relationships with international blue-chip OEMs.

About Eurazeo
Eurazeo is a leading European investment group with €40 billion in diversified assets under management, of which €31 billion is managed on behalf of institutional investors and private clients. Its investments span private equity, private debt, real estate and infrastructure strategies. With more than 450 employees across 16 offices worldwide, Eurazeo supports over 650 mid-market companies through deep sector expertise, access to global markets, and a responsible, growth-oriented approach to value creation. A stable shareholder base of institutional investors and family offices, together with a solid capital base, underpins Eurazeo’s long-term development.

This press release is solely for the use of members of the media and should not be relied upon by personal investors, financial advisers or institutional investors.
Issued by Rantum Capital Management GmbH (reg no. HRB94787 at Maintor Panorama, Neue Mainzer Str. 2-4, 60311 Frankfurt, Germany).
Sources: Eurazeo, 30 June 2026; Tontarra; Getsch+Hiller Medizintechnik.